Summary:
This is a placebo-controlled outpatient study that assess the efficacy of an investigational compound for the treatment of Schizophrenia. The study consists of a 12-week treatment period, in which participants will be assigned to receive the investigational compound or placebo. Following completion of the treatment period, there is 2-week follow up period.
Qualified Participants Must:
• Be between the ages of 18-55
•
Have a diagnosis of Schizophrenia
•
Have no recent hospitalizations for worsening of schizophrenia symptoms
•
Be on treatment with antipsychotics
•
Be medically stable
Qualified Participants May Receive:
Compensation is available for all study participants